Zim Laboratories
ZIMLABNSE

Zim Laboratories

₹103.491.42 (1.39%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
100.00
Today’s high
105.00
52 week low
59.31
52 week high
127.00
Open price
102.07
Previous close
102.07
Live volume
11,344
Lower circuit
96.97
Upper circuit
107.17

Fundamentals

Market Cap
₹546Cr
ROE
1.97%
P/E Ratio(TTM)
93.58
EPS(TTM)
1.09
P/B Ratio
1.84
Dividend Yield
0.00%
Industry P/E
33.73
Book Value
55.31
Debt to Equity
0.42
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹111
+0.97%
Profit (Cr)
₹3.74
-15.00%
-25025100225
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+1%
3Y CAGR+4%
Profit growthValue
1Y (TTM)-23%
3Y CAGR-6%

About

Established in 1989, ZIM Laboratories Limited is a research-focused Indian company recognized globally for its innovative drug delivery solutions and complex generic products. The company's vision is to make quality healthcare affordable and accessible through drug delivery systems that prioritize patient convenience and improve treatment adherence. It specializes in developing and manufacturing differentiated oral solid dosage forms using proprietary, non-infringing technologies and Novel Drug Delivery Techniques (NDDS). The business operates in two primary segments, with Pharmaceuticals contributing 75% of the total operating income in the fiscal year 2025. The Nutraceuticals division, which offers vitamins and dietary supplements, accounted for the other 25% of the company's operating income during the same period. To drive its innovation-led strategy, the company dedicated 8.8% of its total operating income to research and development activities in fiscal year 2025.;
CEO/MD
Dr. Anwar S.Daud
Founded in
1984
NSE symbol
ZIMLAB

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Retail And Others
69.58%
Promoters
30.34%
Other Domestic Institutions
0.07%
Livesquawk
Zim Laboratories' Q4 EBITDA drops to ₹72M from ₹146M YoY. Q4 EBITDA margin declines to 6.8% from 13.4% YoY.
2026
19
May
Annual Result
Release date
11
Feb
Quarterly Result
Release date
2025
12
Nov
Quarterly Result
Release date
7
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks